As long as the price of insulin matters, the word "dispute" is inseparable.

On July 13th, local time in the United States, some media reported that due to suspected “fraud” and “increasing the price of insulin drugs”, the three major insulin giants Sanofi, Novo Nordisk, Eli Lilly, and several pharmacy managers are facing Class action lawsuits by multiple drug distributors.

In response to foreign media, Sanofi mentioned that "the current allegations are unfounded."

Oligopoly and high prices are the main reasons for the controversy. In 2020, affected by the new crown epidemic, the United States closed its borders and the "I am not a medicine god" incident was staged in the United States. Patients illegally crossed the border to Canada, Mexico and other places to obtain cheap drugs.

In China, the three giants that have monopolized the insulin market for 15 years have also repeatedly fallen into trouble. Just last month, Sanofi was punished by Sichuan Provincial People's Hospital for "stop purchasing related products, delaying or stopping payment for goods" for illegal sales of drug substitutes.

This accusation just uncovered the ugly scars behind the insulin market once again.